Current Report Filing (8-k)
September 15 2016 - 04:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): September 14, 2016
Sage Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE
|
|
001-36544
|
|
27-4486580
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
215 First Street
Cambridge, MA
|
|
02142
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code (617) 299-8380
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01 Other Events.
On September 14, 2016, Sage Therapeutics, Inc. (the Company), completed the sale of 5,062,892 shares of its common stock to the underwriters
as part of the Companys previously announced public offering at the public offering price of $39.75 per share, less underwriting discounts and commissions, including the exercise in full by the underwriters of their option to purchase up to
660,377 additional shares of common stock of the Company. The Companys proceeds raised in the offering, after underwriting discounts and commissions, and before estimated expenses of the offering, were approximately $189.2 million.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
Date: September 15, 2016
|
|
|
|
SAGE THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Anne Marie Cook
|
|
|
|
|
|
|
|
|
Anne Marie Cook
Senior Vice President,
General Counsel
|
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Feb 2024 to Mar 2024
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Mar 2023 to Mar 2024